CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-29 | Dandekar Atul CSBO | Sale 10b5-1 | −7,100 | $27.31 | $194K | 26,650 |
| 2026-07-29 | Dandekar Atul CSBO | Sale 10b5-1 | −400 | $27.89 | $11K | 26,250 |
| 2026-07-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 21,643 | ||
| 2026-07-01 | Bernstein Harold President, R&D & CMO | Option exercise 10b5-1 | +14,609 | $10.42 | $152K | 14,609 |
| 2026-07-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −13,409 | $29.87 | $400K | 1,200 |
| 2026-07-01 | Bernstein Harold President, R&D & CMO | Sale 10b5-1 | −1,200 | $30.34 | $36K | 0 |
| 2026-07-01 | Bernstein Harold President, R&D & CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,609 | 192,945 | ||
| 2026-07-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −2,593 | $29.98 | $78K | 23,337 |
| 2026-07-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −30,311 | $29.95 | $908K | 288,768 |
| 2026-07-01 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −1,597 | $30.44 | $49K | 287,171 |
| 2026-06-29 | Dandekar Atul CSBO | Option exercise 10b5-1 | +7,500 | $10.42 | $78K | 33,750 |
| 2026-06-29 | Dandekar Atul CSBO | Sale 10b5-1 | −7,500 | $28.02 | $210K | 26,250 |
| 2026-06-29 | Dandekar Atul CSBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 29,143 | ||
| 2026-06-23 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −23,865 | $26.05 | $622K | 319,079 |
| 2026-06-22 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −1,953 | $26.00 | $51K | 342,944 |
| 2026-06-22 | Coloma Jason V Chief Executive Officer | Sale 10b5-1 | −2,040 | $26.00 | $53K | 25,930 |
| 2026-06-08 | Andrews Nancy C Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2026-06-08 | Hoppenot Herve Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2026-06-08 | Lim Jonathan E Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2026-06-08 | SPIEGELMAN DANIEL K Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 |
Page 4 of 14 · 267 trades